{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T14:08:39Z","timestamp":1782310119608,"version":"3.54.5"},"reference-count":30,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T00:00:00Z","timestamp":1741046400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.clml.2025.03.003","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:31:15Z","timestamp":1741134675000},"page":"532-538","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Outcomes of Newly Diagnosed Multiple Myeloma Patients Requiring Dialysis"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0618-8900","authenticated-orcid":false,"given":"Despina","family":"Fotiou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Foteini","family":"Theodorakakou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eirini","family":"Solia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliki","family":"Spiliopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6328-9783","authenticated-orcid":false,"given":"Ioannis","family":"Ntanasis-Stathopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Malandrakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erasmia","family":"Psimenou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Kanellias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Roussou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalini","family":"Migkou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Eleutherakis-Papaiakovou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7857-5427","authenticated-orcid":false,"given":"Angeliki","family":"Andrikopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stavroula","family":"Giannouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6244-1229","authenticated-orcid":false,"given":"Maria","family":"Gavriatopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Terpos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efstathios","family":"Kastritis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8990-3254","authenticated-orcid":false,"given":"Meletios A.","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"33","key":"10.1016\/j.clml.2025.03.003_bib0001","doi-asserted-by":"crossref","first-page":"4976","DOI":"10.1200\/JCO.2010.30.8791","article-title":"Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group","volume":"28","author":"Dimopoulos","year":"2010","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clml.2025.03.003_bib0002","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1093\/ndt\/gfp679","article-title":"Incidence and outcome of patients starting renal replacement therapy for end-stage renal disease due to multiple myeloma or light-chain deposit disease: an ERA-EDTA Registry study","volume":"25","author":"Tsakiris","year":"2010","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"10.1016\/j.clml.2025.03.003_bib0003","doi-asserted-by":"crossref","first-page":"e296","DOI":"10.1038\/bcj.2015.20","article-title":"Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma","volume":"5","author":"Gonsalves","year":"2015","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1016\/j.clml.2025.03.003_bib0004","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in Renal Disease Study Group","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med"},{"issue":"8","key":"10.1016\/j.clml.2025.03.003_bib0005","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.clml.2025.03.003_bib0006","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1016\/S2352-3026(19)30014-6","article-title":"High cutoff versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (EuLITE): a phase 2 randomised controlled trial","volume":"6","author":"Hutchison","year":"2019","journal-title":"Lancet Haematol"},{"issue":"21","key":"10.1016\/j.clml.2025.03.003_bib0007","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1001\/jama.2017.17924","article-title":"Effect of high-cutoff hemodialysis vs conventional hemodialysis on hemodialysis independence among patients with myeloma cast nephropathy: a randomized clinical trial","volume":"318","author":"Bridoux","year":"2017","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.clml.2025.03.003_bib0008","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/ajh.24335","article-title":"Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis","volume":"91","author":"Dimopoulos","year":"2016","journal-title":"Am J Hematol"},{"issue":"10","key":"10.1016\/j.clml.2025.03.003_bib0009","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.3324\/haematol.11463","article-title":"Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma","volume":"92","author":"Ludwig","year":"2007","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.clml.2025.03.003_bib0010","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/leu.2012.182","article-title":"The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma","volume":"27","author":"Dimopoulos","year":"2013","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.clml.2025.03.003_bib0011","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1681\/ASN.2010080857","article-title":"Early reduction of serum-free light chains associates with renal recovery in myeloma kidney","volume":"22","author":"Hutchison","year":"2011","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.clml.2025.03.003_bib0012","doi-asserted-by":"crossref","first-page":"e571","DOI":"10.1038\/bcj.2017.49","article-title":"Outcomes of newly diagnosed myeloma patients requiring dialysis: renal recovery, importance of rapid response and survival benefit","volume":"7","author":"Dimopoulos","year":"2017","journal-title":"Blood Cancer J"},{"issue":"12","key":"10.1016\/j.clml.2025.03.003_bib0013","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.1158\/0008-5472.CAN-17-0502","article-title":"An ex vivo platform for the prediction of clinical response in multiple myeloma","volume":"77","author":"Silva","year":"2017","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.clml.2025.03.003_bib0014","doi-asserted-by":"crossref","first-page":"e415","DOI":"10.1016\/j.clml.2019.05.010","article-title":"Renal impairment at diagnosis in myeloma: patient characteristics, treatment, and impact on outcomes. Results from the Australia and New Zealand Myeloma and Related diseases registry","volume":"19","author":"Ho","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"10.1016\/j.clml.2025.03.003_bib0015","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41408-022-00732-3","article-title":"Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: results of the iStopMM study","volume":"12","author":"Long","year":"2022","journal-title":"Blood Cancer J"},{"issue":"7","key":"10.1016\/j.clml.2025.03.003_bib0016","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/ajh.24035","article-title":"Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment","volume":"90","author":"Zannetti","year":"2015","journal-title":"Am J Hematol"},{"issue":"9","key":"10.1016\/j.clml.2025.03.003_bib0017","doi-asserted-by":"crossref","first-page":"E226","DOI":"10.1002\/ajh.27001","article-title":"Prospective phase 2 trial of daratumumab with dexamethasone in patients with relapsed\/refractory multiple myeloma and severe renal impairment or on dialysis: the DARE study","volume":"98","author":"Kastritis","year":"2023","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.clml.2025.03.003_bib0018","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3324\/haematol.2013.087585","article-title":"Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65\/GMMG-HD4 trial","volume":"99","author":"Scheid","year":"2014","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.clml.2025.03.003_bib0019","doi-asserted-by":"crossref","first-page":"65","DOI":"10.5045\/br.2020.55.1.65","article-title":"Daratumumab in dialysis-dependent multiple myeloma","volume":"55","author":"Jeyaraman","year":"2020","journal-title":"Blood Res"},{"issue":"8","key":"10.1016\/j.clml.2025.03.003_bib0020","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/sj.bmt.1704440","article-title":"Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant","volume":"33","author":"Lee","year":"2004","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"10.1016\/j.clml.2025.03.003_bib0021","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1038\/bmt.2017.198","article-title":"Autologous hematopoietic cell transplantation for multiple myeloma patients with renal insufficiency: a center for international blood and marrow transplant research analysis","volume":"52","author":"Mahindra","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.clml.2025.03.003_bib0022","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.bbmt.2009.03.021","article-title":"Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma","volume":"15","author":"Parikh","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.clml.2025.03.003_bib0023","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1159\/000486890","article-title":"Autologous hematopoietic cell transplantation for dialysis-dependent myeloma: more efficient, less toxic","volume":"139","author":"Amit","year":"2018","journal-title":"Acta Haematol"},{"issue":"3","key":"10.1016\/j.clml.2025.03.003_bib0024","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1093\/ndt\/gfz211","article-title":"Incidence, prognostic impact and clinical outcomes of renal impairment in patients with multiple myeloma: a population-based registry","volume":"36","author":"Courant","year":"2021","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1016\/j.clml.2025.03.003_bib0025","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1046\/j.1365-2141.1996.5191061.x","article-title":"Presenting features and prognosis in 72 patients with multiple myeloma who were younger than 40 years","volume":"93","author":"Blade","year":"1996","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.clml.2025.03.003_bib0026","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1600-0609.2009.01318.x","article-title":"Detection of renal impairment as one specific comorbidity factor in multiple myeloma: multicenter study in 198 consecutive patients","volume":"83","author":"Kleber","year":"2009","journal-title":"Eur J Haematol"},{"issue":"46","key":"10.1016\/j.clml.2025.03.003_bib0027","doi-asserted-by":"crossref","first-page":"e5202","DOI":"10.1097\/MD.0000000000005202","article-title":"Bortezomib-based treatment for multiple myeloma patients with renal impairment: a systematic review and meta-analysis of observational studies","volume":"95","author":"Zhu","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"10.1016\/j.clml.2025.03.003_bib0028","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3892\/ol.2024.14267","article-title":"Clinical implications and predictive value of the creatinine\u2011cystatin C ratio in patients with multiple myeloma and renal impairment","volume":"27","author":"Sun","year":"2024","journal-title":"Oncol Lett"},{"key":"10.1016\/j.clml.2025.03.003_bib0029","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1188\/11.CJON.S1.66-76","article-title":"Renal complications in multiple myeloma and related disorders: survivorship care plan of the International Myeloma Foundation Nurse Leadership Board","volume":"15","author":"Faiman","year":"2011","journal-title":"Clin J Oncol Nurs"},{"key":"10.1016\/j.clml.2025.03.003_bib0030","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jocn.2019.07.005","article-title":"Long-term treatment outcomes of patients with primary optic nerve sheath meningioma treated with stereotactic radiotherapy","volume":"68","author":"Ratnayake","year":"2019","journal-title":"J Clin Neurosci"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025000795?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025000795?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T13:52:12Z","timestamp":1749477132000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025000795"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S2152265025000795"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.03.003","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes of Newly Diagnosed Multiple Myeloma Patients Requiring Dialysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}